NEW YORK, N.Y. – The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.
Week of November 9:
Advanced Accelerator Applications S.A. – Saint Genis Pouilly, France, 4.7 million American depositary shares, each representing 2 ordinary shares, priced $15 to $17, managed by Citigroup, and Jefferies. Proposed Nasdaq symbol AAAP. Business: Radiopharmaceutical diagnostics company developing its first therapeutic product.
Equity Bancshares Inc. – Wichita, Kan., 1.79 million class A shares, priced $22 to $24, managed by Keefe Bruyette Woods, and Stephens. Proposed Nasdaq symbol EQBK. Commercial bank with $1.4 billion in assets and 25 locations in Kansas and Missouri.
Instructure Inc. – Salt Lake City, Utah, 4.4 million shares, priced $16 to $18, managed by Morgan Stanley, and Goldman Sachs. Proposed NYSE symbol INST. Business: Operates an online learning management system for academic/corporate clients.
LoanDepot Inc. – Foothill Ranch, Calif., 30 million class A shares, priced $16 to $18, managed by Morgan Stanley, and Goldman Sachs. Proposed NYSE symbol LDI. Business: Nonbank consumer lender focused on originating and selling home loans.
Mesoblast Ltd. – Melbourne, Australia, 5.7 million American depositary shares, each representing 5 ordinary shares, priced at $12.10 each, managed by J.P. Morgan, and Credit Suisse. Proposed Nasdaq symbol MESO. Business: Developing regenerative medicine based on adult stem cells.
Voyager Therapeutics Inc. – Cambridge, Mass., 4.7 million shares, priced $15 to $17, managed by Cowen & Co., and Piper Jaffray. Proposed Nasdaq symbol VYGR. Business: Gene therapy biotech targeting Parkinson’s disease and other CNS disorders.
Wave Life Sciences Pte. Ltd.- Singapore, 5 million ordinary shares, priced $15 to $17, managed by Jefferies, and Leerink. Proposed Nasdaq symbol WVE. Business: Preclinical biotech developing optimized RNA therapies for rare diseases.